Pulmonary but not subcutaneous vaccination confers protection to TB susceptible mice by an IL17-dependent mechanism.

Aguiló, N (Universidad de Zaragoza) ; Álvarez-Arguedas, S (Universidad de Zaragoza) ; Uranga, S (Universidad de Zaragoza) ; Marinova, D (Universidad de Zaragoza) ; Monzón, M (Universidad de Zaragoza) ; Badiola, J (Universidad de Zaragoza) ; Martín, C (Universidad de Zaragoza)
Pulmonary but not subcutaneous vaccination confers protection to TB susceptible mice by an IL17-dependent mechanism.
Financiación H2020 / H2020 Funds
Resumen: Some of the most promising novel tuberculosis vaccine strategies currently under development are based on respiratory vaccination, mimicking the natural route of infection. In this work, we have compared pulmonary and subcutaneous delivery of BCG vaccine in the tuberculosis-susceptible DBA/2 mouse strain, a model in which parenterally administered BCG vaccine does not protect against tuberculosis. Our data show that intranasally but not subcutaneously administered BCG confers robust protection against pulmonary tuberculosis challenge. In addition, our results indicate that pulmonary vaccination triggers a Mycobacterium tuberculosis–specific mucosal immune response orchestrated by interleukin 17A (IL-17A). Thus, IL-17A neutralization in vivo reduces protection and abrogates M. tuberculosis–specific immunoglobulin A (IgA) secretion to respiratory airways and lung expression of polymeric immunoglobulin receptor induced following intranasal vaccination. Together, our results demonstrate that pulmonary delivery of BCG can overcome the lack of protection observed when BCG is given parenterally, suggesting that respiratory tuberculosis vaccines could have an advantage in tuberculosis-endemic countries, where intradermally administered BCG has inefficient effectiveness against pulmonary tuberculosis.
Idioma: Inglés
DOI: 10.1093/infdis/jiv503
Año: 2016
Publicado en: JOURNAL OF INFECTIOUS DISEASES 213, 5 (2016), 831-839
ISSN: 0022-1899

Factor impacto JCR: 6.273 (2016)
Categ. JCR: IMMUNOLOGY rank: 23 / 150 = 0.153 (2016) - Q1 - T1
Categ. JCR: MICROBIOLOGY rank: 15 / 124 = 0.121 (2016) - Q1 - T1
Categ. JCR: INFECTIOUS DISEASES rank: 7 / 84 = 0.083 (2016) - Q1 - T1

Factor impacto SCIMAGO: 3.931 - Infectious Diseases (Q1) - Immunology and Allergy (Q1)

Financiación: info:eu-repo/grantAgreement/EC/H2020/643381/EU/TBVAC2020; Advancing novel and promising TB vaccine candidates from discovery to preclinical and early clinical development/TBVAC2020
Financiación: info:eu-repo/grantAgreement/ES/MINECO/BIO2014-5258P
Tipo y forma: Article (PostPrint)
Área (Departamento): Área Microbiología (Dpto. Microb.Med.Pr.,Sal.Públ.)
Área (Departamento): Area Histología (Dpto. Anatom.Histolog.Humanas)
Área (Departamento): Área Sanidad Animal (Dpto. Patología Animal)
Área (Departamento): Proy. investigación HQA (Dpto. Microb.Med.Pr.,Sal.Públ.)

Rights Reserved All rights reserved by journal editor

Exportado de SIDERAL (2020-02-21-13:34:46)

Este artículo se encuentra en las siguientes colecciones:

 Record created 2016-09-15, last modified 2020-02-21

Rate this document:

Rate this document:
(Not yet reviewed)